Cambridge’s Acceleron, Celgene say blood disorder drug meets mark in trial
July 10, 2018 at 10:06 AM EDT
The companies said they plan to seek FDA approval next year for the drug, a treatment for beta-thalassemia patients who are dependent on blood transfusions.
